- Bazedoxifene
-
- $85.00 / 1kg
-
2024-05-10
- CAS:198481-32-2
- Min. Order: 10kg
- Purity: 0.99
- Supply Ability: 20tons
- Bazedoxifene
-
- $0.00 / 1KG
-
2023-11-27
- CAS:198481-32-2
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 20 TONS
- Bazedoxifene
-
- $1.00 / 1KG
-
2019-09-19
- CAS:198481-32-2
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 100KG
|
| | Bazedoxifene Basic information |
| Product Name: | Bazedoxifene | | Synonyms: | 1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methyl-indol-5-ol;1-((4-(2-Hexahydro-1H-azepin-1-yl)ethoxy)phenyl)methyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol;1H-Indol-5-ol, 1-((4-(2-(hexahydro-1H-azepin-1-yl)ethoxy)phenyl)methyl)-2-(4-hydroxyphenyl)-3-methyl-;Bazedoxifene;Bazedoxifene [inn];Bazedoxifeno;Bazedoxifeno [inn-spanish];Tse-424 | | CAS: | 198481-32-2 | | MF: | C30H34N2O3 | | MW: | 470.6 | | EINECS: | 805-732-1 | | Product Categories: | Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals | | Mol File: | 198481-32-2.mol |  |
| | Bazedoxifene Chemical Properties |
| Melting point | 98-102° | | Boiling point | 694.4±55.0 °C(Predicted) | | density | 1.19 | | storage temp. | Sealed in dry,Store in freezer, under -20°C | | solubility | Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly) | | form | Solid | | pka | 10.12±0.15(Predicted) | | color | White to Very Dark Beige |
| | Bazedoxifene Usage And Synthesis |
| Uses | Bazedoxifene is an nonsteroidal selective estrogen receptor modulator (SERM). Bazedoxifene is used as an antiosteoporotic. | | Definition | ChEBI: Bazedoxifene is a phenylindole. | | General Description | Bazedoxifene, 1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol (Viviant), was declared to be “approvable” bythe FDA in 2007 for the prevention of postmenopausalosteoporosis. As of mid-2009, final approval in the UnitedStates is still pending. Bazedoxifene was approved inEurope in 2009 for the treatment of post–menopausalosteoporosis. | | Clinical Use | Bazedoxifene is an indole-based SERM that is under investigation for the treatment and prevention of
postmenopausal osteoporosis. It also is being evaluated in combination with Premarin (conjugated
estrogens). Bazedoxifene displaces 17β-estradiol from estrogen receptors and has excellent binding affinity for
the receptor itself. Unlike raloxifene, this agent does not cause hot flashes at the doses required to have a
beneficial effect on bone. In addition, it does not cause uterine or mammary gland stimulation. | | Enzyme inhibitor | This potent and selective estrogen receptor modulator, or SERM (FW =
530.65 g/mol; CAS 198481-33-3; Solubility: 00 mM in DMSO), also named
1-[[4-[2- (hexahydro-1H-azepin-1-yl) ethoxy]phenyl]methyl]-2- (4-
hydroxyphenyl) -3-methyl-1H-indol-5-ol, selectivity targets the extrogen
receptor ERα (IC50 = 26 nM), with weaker action against ERβ (IC50 = 99
nM), inhibiting 17β-estradiol-induced proliferation of MCF-7 cells.
Bazedoxifene represents a promising new treatment for osteoporosis, one
with a potential for less uterine and vasomotor effects than selective
estrogen receptor modulators now used clinically. | | target | estrogen receptor |
| | Bazedoxifene Preparation Products And Raw materials |
|